ESSA Pharma(EPIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPIX ESSA Pharma

Halted 10-08 16:00:00 EDT

0.2012

+0.0000

0.00%

High0.2012	Low0.2012	Vol0.00
Open0.2012	D1 Closing0.2012	Amplitude0.00%
Mkt Cap9.52M	Tradable Cap5.25M	Total Shares47.31M
T/O1.16M	T/O Rate0.00%	Tradable Shares26.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPIX","market":"US","secType":"STK","nameCN":"ESSA Pharma","latestPrice":0.2012,"timestamp":1759953600000,"preClose":0.2012,"halted":3,"volume":0,"delay":0,"floatShares":26074000,"shares":47308394,"eps":-0.569219,"marketStatus":"Halted","change":0,"latestTime":"10-08 16:00:00 EDT","open":0.2012,"high":0.2012,"low":0.2012,"amount":1164183.85152768,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.569219,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1436414400000,"exchange":"NASDAQ","adjPreClose":0.2012,"volumeRatio":0},"requestUrl":"/m/hq/s/EPIX","defaultTab":"news","newsList":[{"id":"2582376301","title":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376301","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376301?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950640,"startTime":"0","endTime":"0","summary":"XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5JJSXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPIX","IE00B64PRP62.GBP","LU2210150020.SGD","BK4539","XOMA","HLVX","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","LVTX"],"gpt_icon":0},{"id":"2574115641","title":"ESSA Pharma Inc to be delisted from Nasdaq following acquisition by XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2574115641","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574115641?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:01","pubTimestamp":1760007700,"startTime":"0","endTime":"0","summary":"ESSA Pharma Inc. has announced that, following its acquisition by XenoTherapeutics, it has requested the Nasdaq Capital Market to file a delisting application for its common shares. The company expects to terminate registration of its shares approximately 10 days after the closing of the acquisition, which was completed on October 9, 2025. An early warning report regarding the transaction will be filed on SEDAR+.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL4Z5l01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2574103156","title":"Press Release: ESSA Announces Completion of Arrangement with XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2574103156","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574103156?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:01","pubTimestamp":1760007660,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc.   today announced the completion of XenoTherapeutics'  previously announced acquisition of ESSA .Xeno Acquisition Corp., a wholly owned subsidiary of Xeno, has acquired all of the outstanding common shares of ESSA  for approximately US$0.1242 per Common Share, plus one contingent value right  per Common Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Acquisition. The potential CVR payment of US$0.14 per Common Share represents up to US$6.7 million in the aggregate that may be distributed to CVR holders depending on the outcome and related expenses of certain contingent liabilities.An early warning report will be filed on SEDAR+ at www.sedarplus.ca under the Company's profile.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","ESSA","BK4195","EPIX","BK4211","BK4139"],"gpt_icon":0},{"id":"2573414989","title":"BRIEF-Essa Securityholders Approve Acquisition By Xenotherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2573414989","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573414989?lang=en_us&edition=fundamental","pubTime":"2025-10-07 06:12","pubTimestamp":1759788774,"startTime":"0","endTime":"0","summary":"BRIEF-Essa Securityholders Approve Acquisition By XenotherapeuticsOct 6 (Reuters) - ESSA Pharma Inc EPIX.O:ESSA SECURITYHOLDERS APPROVE ACQUISITION BY XENOTHERAPEUTICSSource text: ID:nCNWNqb8daFurther company coverage: EPIX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA447GTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPIX","BK4139"],"gpt_icon":0},{"id":"2573375989","title":"ESSA Pharma Shareholders Approve Acquisition by XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2573375989","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573375989?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:58","pubTimestamp":1759787906,"startTime":"0","endTime":"0","summary":"ESSA Pharma (EPIX) won near-unanimous shareholder approval for its acquisition by XenoTherapeutics.The transaction remains subject to the approval of the Supreme Court of British Columbia and other cl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4211","EPIX","ESSA","BK4195"],"gpt_icon":0},{"id":"2573986542","title":"Essa Pharma shareholders approve acquisition by XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2573986542","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573986542?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:20","pubTimestamp":1759785606,"startTime":"0","endTime":"0","summary":"ESSA Pharma (EPIX) announces that its Securityholders have approved the acquisition of all of the issued and outstanding common shares of the Compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/essa-pharma-shareholders-approve-acquisition-by-xenotherapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/essa-pharma-shareholders-approve-acquisition-by-xenotherapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2573985073","title":"ESSA Pharma Inc. Held Special Meeting of Securityholders Regarding Acquisition by XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2573985073","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573985073?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:15","pubTimestamp":1759785329,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via CNW  on October 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLbgsFd4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ESSA Pharma Inc. Held Special Meeting of Securityholders Regarding Acquisition by XenoTherapeutics","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2573598681","title":"ESSA Securityholders Approve Acquisition by Xenotherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2573598681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573598681?lang=en_us&edition=fundamental","pubTime":"2025-10-07 05:15","pubTimestamp":1759785317,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA3NH06G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPIX","BK4139"],"gpt_icon":0},{"id":"2572372324","title":"ESSA Pharma Receives Court Approval for Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2572372324","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572372324?lang=en_us&edition=fundamental","pubTime":"2025-10-01 05:01","pubTimestamp":1759266080,"startTime":"0","endTime":"0","summary":"ESSA Pharma ( ($EPIX) ) has shared an update. On September 30, 2025, ESSA Pharma Inc. announced that it received an amended Interim Order from the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/essa-pharma-receives-court-approval-for-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/essa-pharma-receives-court-approval-for-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESSA","BK4211","EPIX","BK4139","BK4195"],"gpt_icon":0},{"id":"2572374973","title":"Essa Pharma provides update on combination agreement with Xeno","url":"https://stock-news.laohu8.com/highlight/detail?id=2572374973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572374973?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:40","pubTimestamp":1759264859,"startTime":"0","endTime":"0","summary":"ESSA Pharma (EPIX) announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics, a non-profit b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/essa-pharma-provides-update-on-combination-agreement-with-xeno-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/essa-pharma-provides-update-on-combination-agreement-with-xeno-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2572710123","title":"ESSA Pharma Inc. Provides Update on Its Application to the Supreme Court of British Columbia for Amended Interim Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2572710123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572710123?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:31","pubTimestamp":1759264304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUA2XFXYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPIX","BK4139"],"gpt_icon":0},{"id":"2572374883","title":"ESSA Pharma Provides Update on Special Meeting and Court Approvals for XenoTherapeutics Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2572374883","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572374883?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:31","pubTimestamp":1759264298,"startTime":"0","endTime":"0","summary":"ESSA Pharma Inc. announced an update regarding its previously disclosed transaction with XenoTherapeutics Inc., under which XenoTherapeutics will acquire all issued and outstanding common shares of ESSA. According to ESSA, the Supreme Court of British Columbia has issued an amended Interim Order approving key dates related to the transaction, including the special meeting of shareholders, optionholders, and warrantholders set for October 3, 2025. The court hearing to approve the arrangement is scheduled for October 7, 2025. ESSA has also filed supplemental proxy materials reflecting the revised terms of the transaction on its profiles on EDGAR and SEDAR+.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the ori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLc7ZtpV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2569070555","title":"Essa Pharma amends business combination agreement with XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2569070555","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569070555?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:05","pubTimestamp":1758711922,"startTime":"0","endTime":"0","summary":"ESSA Pharma (EPIX) announced that it has reached an agreement to amend its previously announced business combination agreement with XenoTherapeutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/essa-pharma-amends-business-combination-agreement-with-xenotherapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/essa-pharma-amends-business-combination-agreement-with-xenotherapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPIX"],"gpt_icon":0},{"id":"2569777779","title":"BRIEF-ESSA Pharma Amends Agreement with XenoTherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2569777779","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569777779?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:06","pubTimestamp":1758708395,"startTime":"0","endTime":"0","summary":"BRIEF-ESSA Pharma Amends Agreement with XenoTherapeuticsSept 24 (Reuters) - ESSA Pharma Inc EPIX.O:ESSA PHARMA INC. AMENDS AGREEMENT WITH XENOTHERAPEUTICSESSA PHARMA INC - SHAREHOLDERS TO RECEIVE $0.1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA5HKDZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA","BK4139","EPIX"],"gpt_icon":1},{"id":"2569777136","title":"ESSA Pharma Updates Terms of XenoTherapeutics Deal, Lowers Shareholder Payout and Adjourns Special Meeting to October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2569777136","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569777136?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:00","pubTimestamp":1758708052,"startTime":"0","endTime":"0","summary":"ESSA Pharma Inc. has announced an amendment to its previously disclosed agreement with XenoTherapeutics Inc. Under the revised terms, ESSA shareholders are now expected to receive approximately $0.12 per share in cash at closing, in addition to a contingent value right  that could provide up to approximately $0.14 per share, depending on certain conditions. This update reflects adjustments for potential liabilities, associated expenses, and the company's latest cash balance estimates. The company stated that these changes were made in light of new financial information and will be detailed in supplemental proxy materials to be filed in due course. XOMA Royalty Corporation continues to act as structuring agent and intends to provide financing for the transaction. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL53Zm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPIX","XOMA","BK4139"],"gpt_icon":0},{"id":"2569779427","title":"ESSA Pharma Inc. Amends Agreement With Xenotherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2569779427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569779427?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:00","pubTimestamp":1758708005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA9P57PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPIX","BK4139","XOMA"],"gpt_icon":0},{"id":"2569940777","title":"ESSA Pharma Inc - CVR Represents Right to Receive up to $0.14 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2569940777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569940777?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:00","pubTimestamp":1758708004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA5HKDZT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPIX","BK4139","XOMA"],"gpt_icon":0},{"id":"2569777109","title":"ESSA Pharma Inc - to Apply to Supreme Court to Amend Interim Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2569777109","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569777109?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:00","pubTimestamp":1758708004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA5HKDZT:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPIX","XOMA","BK4139"],"gpt_icon":0},{"id":"2569101777","title":"ESSA Pharma Inc - Adjourns Special Meeting to October 3, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2569101777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569101777?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:00","pubTimestamp":1758708004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA5HKDZT:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XOMA","BK4139","EPIX"],"gpt_icon":0},{"id":"2566708256","title":"BRIEF-ESSA Pharma To Adjourn Special Meeting To September 29, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2566708256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566708256?lang=en_us&edition=fundamental","pubTime":"2025-09-10 18:32","pubTimestamp":1757500376,"startTime":"0","endTime":"0","summary":"BRIEF-ESSA Pharma To Adjourn Special Meeting To September 29, 2025Sept 10 (Reuters) - ESSA Pharma Inc EPIX.O:ESSA PHARMA INC - TO ADJOURN SPECIAL MEETING TO SEPTEMBER 29, 2025ESSA PHARMA INC - ADJOURN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nFWN3UX0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPIX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.essapharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.0084},{"period":"6month","weight":-0.8795},{"period":"1year","weight":-0.8773},{"period":"ytd","weight":-0.8876}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.102519},{"month":2,"riseRate":0.4,"avgChangeRate":0.024211},{"month":3,"riseRate":0.4,"avgChangeRate":0.008628},{"month":4,"riseRate":0.3,"avgChangeRate":-0.090347},{"month":5,"riseRate":0.6,"avgChangeRate":0.027738},{"month":6,"riseRate":0.3,"avgChangeRate":-0.132951},{"month":7,"riseRate":0.4,"avgChangeRate":-0.05269},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.163543},{"month":9,"riseRate":0.545455,"avgChangeRate":-0.022726},{"month":10,"riseRate":0.545455,"avgChangeRate":0.137942},{"month":11,"riseRate":0.6,"avgChangeRate":-0.015736},{"month":12,"riseRate":0.4,"avgChangeRate":0.032688}],"exchange":"NASDAQ","name":"ESSA Pharma","nameEN":"ESSA Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ESSA Pharma(EPIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ESSA Pharma(EPIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ESSA Pharma,EPIX,ESSA Pharma股票,ESSA Pharma股票老虎,ESSA Pharma股票老虎国际,ESSA Pharma行情,ESSA Pharma股票行情,ESSA Pharma股价,ESSA Pharma股市,ESSA Pharma股票价格,ESSA Pharma股票交易,ESSA Pharma股票购买,ESSA Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ESSA Pharma(EPIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ESSA Pharma(EPIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}